Cantor Fitzgerald Forecasts Omeros FY2026 Earnings

Omeros Co. (NASDAQ:OMER) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Omeros in a report released on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer forecasts that the biopharmaceutical company will post earnings of ($1.14) per share for the year. The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share.

A number of other equities analysts have also commented on the stock. HC Wainwright initiated coverage on shares of Omeros in a research report on Tuesday. They set a “buy” rating and a $9.00 price target on the stock. D. Boral Capital restated a “buy” rating and set a $36.00 target price on shares of Omeros in a research report on Tuesday, May 13th. Wall Street Zen downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research report on Friday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Omeros Stock Performance

OMER opened at $3.77 on Tuesday. The stock has a fifty day moving average of $5.37 and a 200-day moving average of $7.91. The company has a market capitalization of $220.90 million, a P/E ratio of -1.63 and a beta of 2.20. Omeros has a fifty-two week low of $2.97 and a fifty-two week high of $13.60.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.05).

Hedge Funds Weigh In On Omeros

Several hedge funds have recently bought and sold shares of OMER. Raymond James Financial Inc. bought a new stake in shares of Omeros during the 4th quarter worth approximately $124,000. Price T Rowe Associates Inc. MD lifted its stake in Omeros by 12.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,582 shares of the biopharmaceutical company’s stock worth $392,000 after purchasing an additional 4,401 shares during the last quarter. Cerity Partners LLC boosted its holdings in shares of Omeros by 9.9% in the 4th quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 2,600 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Omeros in the 4th quarter valued at $46,000. Finally, Deutsche Bank AG raised its holdings in shares of Omeros by 38.2% during the 4th quarter. Deutsche Bank AG now owns 40,046 shares of the biopharmaceutical company’s stock worth $396,000 after buying an additional 11,068 shares in the last quarter. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.